Candidemia

This Phase 2 trial tested whether adding interferon-gamma to standard antifungal treatment helps clear Candida from the blood faster. 65 adults with candidemia received the drug or standard care alone. The study is completed, and results will show if this combination is safe and …

This study tested an experimental drug called APX001 in 21 adults with Candida bloodstream infections, including cases where standard antifungals might not work. Participants received the drug for up to 14 days, with possible follow-up treatment. The goal was to see if the drug c…

This Phase 2 trial tested an experimental antifungal drug called APX001 (fosmanogepix) in 9 adults with blood or deep-organ infections caused by Candida auris, a fungus that often resists standard treatments. The drug was given by IV or mouth for up to 42 days. The goal was to se…

This pilot study explores whether a PCR-based test can deliver faster results for diagnosing invasive candidiasis in intensive care patients. The trial compares the time to results using this new strategy against standard methods, with the hope of enabling earlier, more targeted …

This study looked at whether combining several blood tests can detect serious fungal infections (candidemia) faster and more accurately than standard methods. Researchers tested 2 hospitalized adults with suspected fungal infections using both routine blood cultures and newer tes…

This study looked at a blood test called Beta-D-glucan (BDG) to see how well it detects invasive fungal infections in people with weak immune systems. Researchers tested 280 patients and checked if two positive results within 15 days confirmed an infection. The goal is to help do…

This study tested a new medicine called rezafungin to see if it can prevent serious fungal infections in adults getting a bone marrow transplant. About 600 participants received either rezafungin or the standard treatment. The goal was to see if rezafungin helps more people stay …